Abstract:Objective To detect the CYP2C9 and VKORC1 genetic polymorphism in patients with atrial fibrillation which accepted anticoagulant therapy with Warfarin,analyze the correlations of the CYP2C9 and VKO-RC1 genetic polymorphism with the effective dose and onset time of Warfarin.Methods 222 patients with permanert non-valvular atrial fibrillation were recruited randomly and divided into different groups according to the results of anticoagulant therapy.About the Warfarin drug sensitivity of patient,we defined the low effective dose when accumulated dose of Warfarin less than 12.5 milligrams if international normalized ratio (INR) reached the target value 1.8-3.0,the high effective dose was accumulated dose of Warfarin more than or equal to 12.5 milligrams.According to this,the patients were divided into low effective dose group and high effective dose group.The shot onset time was the onset time of Warfarin less than 10 days if INR reached the target value 1.8-3.0,the long onset time was the onset time more than or equal to 10 days.According to this,the patients were divided into shot onset time group and long onset time group.The correlations of the CYP2C9 and VKORC1 genetic polymorphism with the effective dose and onset time of Warfarin were analyzed.Results (1)The age,serum creatinine(SCr) and the proportion of patients taking beta blockers in low effective dose group were significantly higher than those in high effective dose group (P＜0.05 or 0.01);the body mass index (BMI),white blood cell (WBC) count significandy lower than high effective dose group(P＜0.05);the genetic makeup of CYP2C9 rs1057910 in the two groups was significantly different(P＜0.05).(2)The age,SCr and brain natriuretic peptide (BNP) of patients in shot onset time group were significantly higher than those in long onset time group(P＜0.05 or 0.01);the BMI,WBC and left ventricular ejection fraction (LVEF) significantly lower than long onset time group (P＜0.05 or 0.01);the genetic makeup of VKORC1 rs9923231 and rs10871454 in the two groups were significantly different(P＜0.05 or 0.01).(3) The effective dose of Warfarin in patients with CYP2C9 rs1057910 CA genotype was significantly lower than that with CYP2C9 rs1057910 AA genotype (P＜0.01),the onset time of Warfarin in patients with VKORC1 rs9923231 and rs10871454 CT genotype were significantly lower than those with VKORC1 rs9923231 and rs10871454 TT genotype (P＜0.05 or 0.01).(4)Based on the influence of CYP2C9 and VKORC1 different genotype on Warfarin effective dose and onset time,we defined Warfarin drug sensitivity as highly sensitivity,low sensitivity and routine sensitivity prediction model.Conclusion Combination CYP2C9 and VKORC1 genetic polymorphism with the clinical setting of patients provided a new method for guiding Warfarin anticoagulant therapy rationally in clinic and provided guidance evidence for using genotype to adjust Warfarin dose.

Research on single nucleotide polymorphism with initial anticoagulative effect and maintenance dose of ;Warfarin

Impact of Gene Polymorphism on the Initiation and Maintenance Phases of Warfarin Therapy in Chinese Patients Undergoing Heart Valve Replacement

Genetic Associations With Stable Warfarin Dose Requirements in Han Chinese Patients

Impact of CYP2C9*3, VKORC1-1639, CYP4F2rs2108622 genetic polymorphism and clinical factors on warfarin maintenance dose in Han-Chinese patients

The Effect of CYP4F2 Polymorphism on Initial Warfarin Dose in Patients with Heart Valve Replacement

Effects of CYP2C9 and VKORC1 Genetic Polymorphisms in Chinese Han Population on Maintenance Dosage of Warfarin

Warfarin Dosage Response Related Pharmacogenetics In Chinese Population

Effect of NPC1L1 Polymorphism on Warfarin Stable Dose in Chinese Patients under Heart Valve Replacement Surgery

Identification of Two Novel Genes SLC15A2 and SLCO1B3 Associated with Maintenance Dose Variability of Warfarin in a Chinese Population

Association between CYP2C9 and VKORC1 genetic polymorphisms and efficacy and safety of warfarin in Chinese patients

Effect of CYP2C9, CYP4F2 and VKORC1 genetic polymorphisms on pharmacokinetics and pharmacodynamics of mean daily maintenance dose of warfarin in Chinese patients

CYP4F2 rs2108622: a minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacement.

EFFECT OF CYP2C9 AND VKORC1 GENE POLYMORPHISM ON WARFARIN STEADY-STATE THERAPEUTIC DOSE AND INDIVIDUAL ANTICOAGULATION EFFICACY

A1640 Effect of CYP2C9 and VKORC1 gene polymorphism on warfarin steady-state therapeutic dose and individual anticoagulation efficacy

To Establish a Method for Detecting Genetic Polymorphism of CYP2C9 1075A>C and VKORC1-1639 G>A and Evaluate the Correlation of SNP with Warfarin Dose

CYP4F2 rs2108622: a minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacement: CYP4F2 rs2108622: a minor significant genetic factor of warfarin dose

The Impact of Gene Polymorphisms on Anticoagulation Control With Warfarin.

Clinical Application Of Pharmacogenetic-Based Warfarin-Dosing Algorithm In Patients Of Han Nationality After Rheumatic Valve Replacement: A Randomized And Controlled Trial

Variability of warfarin dose response associated with CYP2C9 and VKORC1 gene polymorphisms in Chinese patients.

The correlation of the Warfarin drug sensitivity with CYP2C9 and VKORC1 genetic polymorphism in patients with atrial fibrillation

Effect of Multiple Single-Nucleotide Variants in VKORC1 Gene on the Maintenance Doses of Warfarin